Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(1.27)
# 2,577
Out of 4,479 analysts
63
Total ratings
32.88%
Success rate
-12.82%
Average return
Main Sectors:
18 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ITCI Intra-Cellular Therapies | Maintains: Buy | $107 → $113 | $67.99 | +66.20% | 4 | Jun 20, 2024 | |
| CARA Cara Therapeutics | Downgrades: Hold | $10 → $1 | $0.26 | +280.23% | 4 | Jun 13, 2024 | |
| STOK Stoke Therapeutics | Maintains: Buy | $21 → $20 | $13.87 | +44.20% | 3 | May 7, 2024 | |
| GHRS GH Research | Maintains: Buy | $30 → $31 | $11.75 | +163.83% | 3 | May 6, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $154 → $164 | $140.11 | +17.05% | 7 | May 2, 2024 | |
| ANVS Annovis Bio | Maintains: Buy | $36 → $26 | $5.27 | +393.36% | 2 | Apr 30, 2024 | |
| SAGE Sage Therapeutics | Maintains: Hold | $21 → $17 | $11.03 | +54.13% | 3 | Apr 26, 2024 | |
| CRVO CervoMed | Maintains: Buy | $50 → $65 | $16.12 | +303.23% | 2 | Apr 8, 2024 | |
| BTAI BioXcel Therapeutics | Maintains: Buy | $18 → $7 | $1.17 | +498.29% | 3 | Mar 14, 2024 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $40 → $33 | $16.04 | +105.74% | 8 | Mar 12, 2024 | |
| BIIB Biogen | Maintains: Buy | $310 → $305 | $231.77 | +31.60% | 10 | Feb 20, 2024 | |
| ZVRA Zevra Therapeutics | Reiterates: Buy | $20 | $4.51 | +343.46% | 2 | Sep 1, 2023 | |
| CYBN Cybin | Reiterates: Buy | $5 | $0.27 | +1,786.79% | 3 | Sep 1, 2023 | |
| CMPS COMPASS Pathways | Maintains: Buy | $60 → $50 | $5.95 | +740.34% | 1 | Aug 22, 2023 | |
| VYGR Voyager Therapeutics | Maintains: Buy | $10 → $14 | $7.86 | +78.12% | 2 | May 10, 2023 | |
| CLNN Clene | Maintains: Buy | $10 → $6 | $0.36 | +1,580.67% | 2 | Oct 4, 2022 | |
| BHVN Biohaven Pharmaceutical Holding Company | Maintains: Buy | n/a | $35.31 | - | 3 | Aug 3, 2021 | |
| TEVA Teva Pharmaceutical | Upgrades: Buy | n/a | $16.34 | - | 1 | Jan 31, 2017 |
Intra-Cellular Therapies
Jun 20, 2024
Maintains: Buy
Price Target: $107 → $113
Current: $67.99
Upside: +66.20%
Cara Therapeutics
Jun 13, 2024
Downgrades: Hold
Price Target: $10 → $1
Current: $0.26
Upside: +280.23%
Stoke Therapeutics
May 7, 2024
Maintains: Buy
Price Target: $21 → $20
Current: $13.87
Upside: +44.20%
GH Research
May 6, 2024
Maintains: Buy
Price Target: $30 → $31
Current: $11.75
Upside: +163.83%
Neurocrine Biosciences
May 2, 2024
Maintains: Buy
Price Target: $154 → $164
Current: $140.11
Upside: +17.05%
Annovis Bio
Apr 30, 2024
Maintains: Buy
Price Target: $36 → $26
Current: $5.27
Upside: +393.36%
Sage Therapeutics
Apr 26, 2024
Maintains: Hold
Price Target: $21 → $17
Current: $11.03
Upside: +54.13%
CervoMed
Apr 8, 2024
Maintains: Buy
Price Target: $50 → $65
Current: $16.12
Upside: +303.23%
BioXcel Therapeutics
Mar 14, 2024
Maintains: Buy
Price Target: $18 → $7
Current: $1.17
Upside: +498.29%
ACADIA Pharmaceuticals
Mar 12, 2024
Maintains: Buy
Price Target: $40 → $33
Current: $16.04
Upside: +105.74%
Biogen
Feb 20, 2024
Maintains: Buy
Price Target: $310 → $305
Current: $231.77
Upside: +31.60%
Zevra Therapeutics
Sep 1, 2023
Reiterates: Buy
Price Target: $20
Current: $4.51
Upside: +343.46%
Cybin
Sep 1, 2023
Reiterates: Buy
Price Target: $5
Current: $0.27
Upside: +1,786.79%
COMPASS Pathways
Aug 22, 2023
Maintains: Buy
Price Target: $60 → $50
Current: $5.95
Upside: +740.34%
Voyager Therapeutics
May 10, 2023
Maintains: Buy
Price Target: $10 → $14
Current: $7.86
Upside: +78.12%
Clene
Oct 4, 2022
Maintains: Buy
Price Target: $10 → $6
Current: $0.36
Upside: +1,580.67%
Biohaven Pharmaceutical Holding Company
Aug 3, 2021
Maintains: Buy
Price Target: n/a
Current: $35.31
Upside: -
Teva Pharmaceutical
Jan 31, 2017
Upgrades: Buy
Price Target: n/a
Current: $16.34
Upside: -